Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
---|---|---|---|
USD 12.53 Billion | USD 31.34 Billion | 9.6% | 2024 |
The global glucose biosensor market size was worth around USD 12.53 Billion in 2024 and is predicted to grow to around USD 31.34 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 9.6% between 2025 and 2034. The report analyzes the global glucose biosensor market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the glucose biosensor industry.
Glucose biosensors are extensively used to supervise and test the concentration of glucose in the blood of the patient. This makes glucose biosensors an integral part of diabetes management as diabetes is linked to an increase in the blood sugar level over a prolonged period of time.
Thus, it is of paramount importance that glucose biosensor is accurate and reliable in monitoring patients’ blood glucose concentration. Furthermore, an increase in the application of self-monitoring devices has significantly expanded the use of biosensors among diabetic patients. These are widely available even in home-care and outpatient scenarios as minimally invasive devices that monitor glucose levels in individuals.
Increase in the adoption of self-monitoring devices drive market growth
There has been a remarkable surge in the number of people suffering from diabetes resulting in increased expenditure toward regular check-ups, medications, and investment in accurate and effective sugar level monitoring devices. In addition, a surge in the geriatric population across the globe and the hereditary nature of diabetes is further expected to drive the growth of the glucose biosensor industry.
Besides, an increase in the adoption of BGM (Blood Glucose Monitoring) and CGM (Continuous Glucose Monitoring) devices among patients for constructive glucose management bolster the growth of the glucose biosensor industry. Although both devices aim to provide users with superior management of glucose levels in patients, CGM is more extensively used as these devices tend to collect large amounts of data continuously due to the presence of elevated measurement frequency.
Furthermore, apart from offering real-time glucose levels, CGM systems also tend to monitor the current rate of glucose change depending on the previous glucose data. These remarkable perks of self-monitoring devices and the exponential surge in diabetic patients significantly augment the growth of the global glucose biosensor market.
High cost of glucose biosensor devices restrict market growth
Glucose biosensor devices are quite expensive than their other alternatives, which might considerably result in decreased demand among diabetic patients. Besides, the prevalence of innovative glucose monitoring techniques also eliminates the need for needle prick, which might be more feasible for patients. For instance, transdermal Reverse Iontophoresis (RI) is gaining immense traction to track glucose levels in the blood of patients as it is a needle-free technology that is capable of extracting medications and biomolecules through the undamaged skin. Thus, the presence of such convenient and precise measurement devices and processes hinders the growth of the glucose biosensor market during the forecast period.
Persistent technological advancements in glucose biosensors and the growth of telemedicine for diabetic management create ample opportunities for the market
Rapid technological advancements in healthcare are predicted to ramp up the demand for innovative and effective methods of diagnosis. The gold standard method is also increasingly used in the diagnosis and management of diabetes among patients as a considerable blood glucose detection.
Several researchers are devising breakthrough techniques to assess glucose in other forms of bodily fluids where glucose is available in different concentrations. For instance, researchers from Penn State University pioneered an innovative technique where instead of assessing glucose from blood sweat was used, eliminating the tedious and painful needle prick.
A remarkable development in minimally or non-invasive devices for tracking and measuring glucose levels in home-care and outpatient settings is also gaining massive prevalence, especially post the pandemic era, which might create ample opportunities for the growth of the global glucose biosensor market.
Prevalence of stringent regulatory policies from government might act as a challenge to market growth
Various regulators across the globe have incessantly imposed strict policies in the healthcare sector that has adversely curtailed the total number of product approvals, which in turn might act as a challenge and negatively impact the growth of the glucose biosensor industry during the forecast period. Several agencies have mandated necessary performance criteria, operating procedures, guidelines, and standards for the manufacturing and use of glucose biosensor devices. This is done to ensure maximum safety and minimize potential risks when it comes to the applications of these devices by the patients.
The global glucose biosensor market is segmented based on Product Type, Technology, Application, End-user, and region.
Based on Product Type, the global glucose biosensor market is divided into Self-monitoring Blood Glucose (SMBG), Continuous Glucose Monitoring (CGM).
On the basis of Technology, the global glucose biosensor market is bifurcated into Electrochemical, Optical.
By Application, the global glucose biosensor market is split into Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Others.
In terms of End-user, the global glucose biosensor market is categorized into Hospitals, Diagnostic Centers, Homecare, Clinics.
Report Attributes | Report Details |
---|---|
Report Name | Glucose Biosensor Market |
Market Size in 2024 | USD 12.53 Billion |
Market Forecast in 2034 | USD 31.34 Billion |
Growth Rate | CAGR of 9.6% |
Number of Pages | 210 |
Key Companies Covered | F. Hoffmann-La Roche Ltd., Trividia Health, Inc., Abbott, Dexcom Inc., Medtronic, LifeScan IP Holdings, LLC., and Senseonics, Sanofi, Bayer AG, GlySens Incorporated, and Pinnacle Technologies, Inc. among other global players., and others. |
Segments Covered | By Product Type, By Technology, By Application, By End-user, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, The Middle East and Africa (MEA) |
Base Year | 2024 |
Historical Year | 2020 to 2023 |
Forecast Year | 2025 - 2034 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North American Region is expected to dominate the market during the forecast period
Based on region, the North American region held the largest global glucose biosensor market share in 2021, holding about 30.3% of the market share, and is further anticipated to grow at a significant CAGR during the forecast period. The growth of the market in this region is mainly due to the increase in the cases of diabetes among people in this region.
According to the report published by International Diabetes Federation, in 2021, about 32.2 million people suffered from diabetes in the US alone, and the number is further predicted to surge exponentially to 36.2 million by the year 2030. Thus, a significant surge in the geriatric population, an increase in the consumption of sugar, and the prevalence of a sedentary lifestyle among people living in this region drive the growth of the market.
In addition, the availability of advanced healthcare infrastructure, the growing popularity of home & remote monitoring and telemedicine, and persistent technological advancements in the region further bolster the growth of the glucose biosensor market in the region during the forecast period.
The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the glucose biosensor market on a global and regional basis.
The global glucose biosensor market is dominated by players like:
The global glucose biosensor market is segmented as follows;
By Product Type
By Technology
By Application
By End-user
By Region
FrequentlyAsked Questions
Glucose biosensors are extensively used to supervise and test the concentration of glucose in the blood of the patient.
The global glucose biosensor market is expected to grow due to Increasing diabetes prevalence and demand for real-time glucose monitoring boost market growth. Technological advancements in wearable biosensors support innovation.
According to a study, the global glucose biosensor market size was worth around USD 12.53 Billion in 2024 and is expected to reach USD 31.34 Billion by 2034.
The global glucose biosensor market is expected to grow at a CAGR of 9.6% during the forecast period.
North America is expected to dominate the glucose biosensor market over the forecast period.
Leading players in the global glucose biosensor market include F. Hoffmann-La Roche Ltd., Trividia Health, Inc., Abbott, Dexcom Inc., Medtronic, LifeScan IP Holdings, LLC., and Senseonics, Sanofi, Bayer AG, GlySens Incorporated, and Pinnacle Technologies, Inc. among other global players., among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed